Clinical trial
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
NCT00109005 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00109005 |
|---|---|
| Title | Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma |
| Official title | A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Revlimid |
| Enrollment | 17 |
| Start date | Apr 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Apr 22, 2005 |
| Last update posted | Jan 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: